<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103241</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-C2131</org_study_id>
    <nct_id>NCT05103241</nct_id>
  </id_info>
  <brief_title>A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers</brief_title>
  <official_title>Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 40 mg/100 μCi [14C]GP681 in Healthy Chinese Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open-label, and single-dose clinical study to evaluate the&#xD;
      mass balance, biotransformation and pharmacokinetics of [14C]GP681 in healthy Chinese male&#xD;
      volunteers, revealing the overall pharmacokinetic characteristics of GP681 in humans, and&#xD;
      providing a reference for the rational administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, radiolabeled, single-dose study of an oral solution of [14C]GP681(40mg/100μCi) in 6 healthy male volunteer.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Nonrandomized and open labeled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of GP681 in the whole blood and plasma, and the radioactive pharmacokinetics following the single orally administered [14C]GP681 in healthy Chinese male volunteers.</measure>
    <time_frame>Up to 336 hours (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled GP681 recovered in blood and in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14C]GP681 in healthy Chinese male subjects to obtain the mass balance data and the main excretion pathway in human body.</measure>
    <time_frame>Up to 432 hours (approx) from the start of administration.</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled GP681 recovered in urine, faeces and in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of GP681 and its major metabolites (such as GP1707D07) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.</measure>
    <time_frame>Up to 336 hours (approx) from the start of administration.</time_frame>
    <description>The concentrations of GP681 and its major metabolites in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the main metabolites and biotransformation pathway of GP681 following the single orally administered [14C]GP681 in healthy Chinese male volunteers</measure>
    <time_frame>Up to 432 hours (approx) from the start of administration.</time_frame>
    <description>Proportion of different metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety following the single orally administered [14C]GP681 in healthy Chinese male volunteers.</measure>
    <time_frame>Up to 432 hours (approx) from the start of administration.</time_frame>
    <description>Adverse events assessed by NCI-CTCAE v5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]GP681</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] GP681</intervention_name>
    <description>40 mg suspension containing 100μCi of [14C]GP681</description>
    <arm_group_label>[14C]GP681</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects between the ages of 18 and 40years, inclusive;&#xD;
&#xD;
          2. A history of regular bowel movements (average 1or 2 bowel movements per day)&#xD;
&#xD;
          3. Body weight ≥50.0 kg and body mass index (BMI) between19-26 kg/m^2(inclusive);&#xD;
&#xD;
          4. Normal physical examination, vital signs, 12-lead ECG, Chest X-ray images&#xD;
             (anteroposterior) and clinical laboratory values, or any abnormality that is&#xD;
             non-clinically significant;&#xD;
&#xD;
          5. Men must agree to use protocol-specified contraception and also to not donate sperm&#xD;
             throughout the study and for at least half a year after the final dose of study drug&#xD;
&#xD;
          6. Voluntarily sign the informed consent form, understand the trial procedures, and be&#xD;
             willing to comply with all trial procedures and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic conditions or allergic diseases, or a history of allergic&#xD;
             reactions attributed to GP681 or any of the ingredients of its formulation or similar&#xD;
             drugs. Those who cannot follow a uniform diet for special dietary requirements.&#xD;
&#xD;
          2. Subjects with swallowing difficulties, or have diseases such as hemorrhoids, perianal&#xD;
             diseases with regular/bleeding in the stool, habitual constipation or diarrhea,&#xD;
             irritable bowel syndrome and inflammatory bowel diseases, affecting drug absorption,&#xD;
             distribution, metabolism, excretion or the efficacy and safety of the drug.&#xD;
&#xD;
          3. History of gastrointestinal ulcer or bleeding; Or history of any clinically&#xD;
             significant diseases or diseases which may affect the result of this study, such as&#xD;
             gastrointestinal, circulatory, respiratory, endocrine, neurological, urinary,&#xD;
             hematological, immunological, psychiatric and metabolic diseases;&#xD;
&#xD;
          4. History of organic heart disease, heart failure, myocardial infarction, angina&#xD;
             pectoris, unexplained arrhythmia, torsade de pointes ventricular tachycardia,&#xD;
             ventricular tachycardia, prolonged QT syndrome, or symptoms of prolonged QT syndrome&#xD;
             and family history;&#xD;
&#xD;
          5. Patients who have undergone surgery within 6 months before the screening period, or&#xD;
             who have undergone major surgery within 28 days, or whose surgical incision is not&#xD;
             completely healed; Major surgery includes, but is not limited to, any surgery with a&#xD;
             significant risk of bleeding, prolonged general anesthesia, or an open biopsy or&#xD;
             significant traumatic injury;&#xD;
&#xD;
          6. Any positive test result of hepatitis B surface antigen, hepatitis C virus antibody,&#xD;
             anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific&#xD;
             antibody;&#xD;
&#xD;
          7. Received any drugs that inhibit or induce the CYP450 enzyme (i.e.,&#xD;
             inducers-barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, nitroimidazoles,&#xD;
             sedative hypnotics, verapamil, fluoroquinolones, antihistamines) 30 days prior to&#xD;
             screening period;&#xD;
&#xD;
          8. Received any drugs (including Chinese herbal medicine, vitamins and supplements)&#xD;
             within 14 days prior to dosing, or participation in another clinical trial within 3&#xD;
             months before dosing.&#xD;
&#xD;
          9. Those who have lost blood or donated up to 400 mL within 3 months before dosing, or&#xD;
             those who plan to donate blood within 1 month after the end of this study;&#xD;
&#xD;
         10. Smoking more than 10 cigarettes per day;&#xD;
&#xD;
         11. Average weekly intake of alcohol is more than 14 units alcohol (1 units ≈ 360 mL beer,&#xD;
             or 45 mL spirits with 40% content, or 150 mL wine) within the 6 months prior to&#xD;
             dosing, or a positive ethanol breath test at screening;&#xD;
&#xD;
         12. Substance abuse or use of soft drugs (e.g., marijuana) in the 3 months prior to the&#xD;
             screening period or use of hard drugs (e.g., cocaine, amphetamines,&#xD;
             phenylcyclohexidine, etc.) in the 1 year prior to the screening period; Or screening&#xD;
             for positive urine drug abuse (drug) tests;&#xD;
&#xD;
         13. Habitual or excessive consumption (more than 8 cups, 1cup=250mL) of grapefruit juice,&#xD;
             tea, coffee and/or caffeinated beverages;&#xD;
&#xD;
         14. Workers engaged in conditions requiring long-term exposure to radioactivity; Or have&#xD;
             significant radiation exposure (≥2 chest/abdomen CT, or ≥3 other types of X-ray&#xD;
             examinations) within 1 year before this study or have participated in the&#xD;
             radiopharmaceutical labeling test;&#xD;
&#xD;
         15. Subjects with poor compliance, or not suitable for this study as judged by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>age of 18-40 (inclusive)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanmei Liu</last_name>
    <phone>021-54030254</phone>
    <email>ymliu@shxh-centerlab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanmei Liu</last_name>
    </contact>
    <investigator>
      <last_name>Yanmei Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>gangyi Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

